Lutathera is FDA approved as first medicine specifically for pediatric patients with gastro-enteropancreatic neuroendocrine tumors – Novartis
Novartis announced that the FDA approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of pediatric patients 12 years and older with… read more.
